Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JULIE B SCHWARTZBARD

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1578558821
CMS profile
116275
Location
AVENTURA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$70,337.28

209 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JULIE B SCHWARTZBARD

NPI 1578558821 · CMS profile ID 116275

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

AVENTURA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578558821?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JULIE B SCHWARTZBARD, NPI 1578558821, CMS profile ID 116275. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578558821?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JULIE B SCHWARTZBARD, NPI 1578558821, CMS profile ID 116275. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578558821?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JULIE B SCHWARTZBARD, NPI 1578558821, CMS profile ID 116275, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1578558821?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

209 matching records · $70,337.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 209 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 209.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biohaven Pharmaceuticals, Inc. $12.7709/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618147 CMS
Biohaven Pharmaceuticals, Inc. $2.0009/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618149 CMS
Acorda Therapeutics, Inc $1,595.0009/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792556829 CMS
Avanir Pharmaceuticals, Inc. $940.0009/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801059607 CMS
Lilly USA, LLC $900.0009/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818641077 CMS
Neurocrine Biosciences, Inc. $225.0009/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837815297 CMS
Teva Pharmaceuticals USA, Inc. $11.5608/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839467435 CMS
Acorda Therapeutics, Inc $21.4408/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792556827 CMS
Biogen, Inc. $12.0308/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827841625 CMS
Lilly USA, LLC $900.0008/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818616899 CMS
Neurocrine Biosciences, Inc. $1,800.0008/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837815295 CMS
AbbVie Inc. $13.3308/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795996091 CMS
Avanir Pharmaceuticals, Inc. $19.4007/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801050409 CMS
Biohaven Pharmaceuticals, Inc. $2,250.0007/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618141 CMS
Biohaven Pharmaceuticals, Inc. $163.4007/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618143 CMS
Biohaven Pharmaceuticals, Inc. $113.9507/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618145 CMS
AbbVie Inc. $125.0007/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795996085 CMS
AbbVie Inc. $1,625.0007/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795996087 CMS
AbbVie Inc. $109.0807/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795996089 CMS
EMD Serono, Inc. $18.1307/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849198603 CMS
Biohaven Pharmaceuticals, Inc. $9.1707/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618139 CMS
Kyowa Kirin, Inc. $14.3607/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852991871 CMS
AbbVie Inc. $18.3006/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795996083 CMS
Novartis Pharmaceuticals Corporation $22.5206/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813240445 CMS
Amgen Inc. $34.7006/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825482727 CMS
Lilly USA, LLC $900.0006/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818588901 CMS
SK Life Science, Inc. $19.7406/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826853007 CMS
Biohaven Pharmaceuticals, Inc. $50.7906/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618125 CMS
Biohaven Pharmaceuticals, Inc. $51.5606/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618127 CMS
Biohaven Pharmaceuticals, Inc. $66.1806/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618129 CMS
Biohaven Pharmaceuticals, Inc. $2,000.0006/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618131 CMS
Biohaven Pharmaceuticals, Inc. $252.9606/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618133 CMS
Biohaven Pharmaceuticals, Inc. $365.0006/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618135 CMS
Biohaven Pharmaceuticals, Inc. $145.1206/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618137 CMS
Biogen, Inc. $11.6306/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827841643 CMS
Biohaven Pharmaceuticals, Inc. $100.6406/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618121 CMS
Biohaven Pharmaceuticals, Inc. $39.9406/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618123 CMS
Biohaven Pharmaceuticals, Inc. $34.7906/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618119 CMS
Eisai Inc. $19.7706/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817945339 CMS
Neurocrine Biosciences, Inc. $3,150.0006/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837815289 CMS
Neurocrine Biosciences, Inc. $180.8506/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837815291 CMS
Neurocrine Biosciences, Inc. $124.9906/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837815293 CMS
AbbVie Inc. $1,500.0006/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795996081 CMS
Neurocrine Biosciences, Inc. $1,800.0006/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837815287 CMS
Neurocrine Biosciences, Inc. $29.4405/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837815285 CMS
Biohaven Pharmaceuticals, Inc. $2,250.0005/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618113 CMS
Biohaven Pharmaceuticals, Inc. $61.2905/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618115 CMS
Biohaven Pharmaceuticals, Inc. $89.0105/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852618117 CMS
EMD Serono, Inc. $19.1205/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849193529 CMS
AbbVie Inc. $13.8805/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795996079 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $81,585.24 239
PY2020 $71,864.59 209
PY2021 $70,337.28 209
PY2022 $58,905.07 177
PY2023 $86,474.00 117
PY2024 $49,657.74 62
PY2025 $24,828.51 36

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $277,621.75 3
PY2025 Principal investigator $634,787.58 87
PY2024 Recipient $19,430.14 3
PY2024 Principal investigator $2,799,456.07 66
PY2023 Recipient $358.00 2
PY2023 Principal investigator $3,650,373.52 68
PY2022 Recipient $7,770.00 5
PY2022 Principal investigator $2,702,933.44 52
PY2021 Recipient $5,225.00 2
PY2021 Principal investigator $1,515,654.89 51
PY2020 Recipient $5,415.87 5
PY2020 Principal investigator $827,421.14 56
PY2019 Recipient $33,487.46 2
PY2019 Principal investigator $1,019,242.89 133

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

90 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer s Disease No dispute reported 06/30/2026 1202534113
Principal investigator 1 Eisai Inc. $668.70 12/15/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244562041
Principal investigator 1 ABBVIE INC. $265.00 12/11/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202529990
Principal investigator 1 ABBVIE INC. $385.00 12/11/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202529992
Principal investigator 1 ABBVIE INC. $1,969.00 12/05/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202529210
Principal investigator 1 ABBVIE INC. $6,453.20 12/04/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202526572
Principal investigator 1 ABBVIE INC. $1,500.00 12/04/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202526574
Principal investigator 1 ABBVIE INC. $1,500.00 12/04/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202526806
Recipient Amneal Pharmaceuticals LLC $109,417.15 11/20/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530913
Principal investigator 1 Eisai Inc. $668.70 11/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244562049
Principal investigator 1 Roche TCRC, Inc. $873.00 11/13/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682552
Principal investigator 1 ABBVIE INC. $10,004.80 11/04/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202520715
Principal investigator 1 PFIZER INC. $1,950.00 11/04/2025 Non-covered Recipient Entity
Visionary Investigators Network
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228727981
Principal investigator 1 Novo Nordisk AS $4,008.26 10/30/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
NN6535-4725 No dispute reported 06/30/2026 1214103245
Principal investigator 1 Eisai Inc. $8,612.10 10/20/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244562043
Principal investigator 1 Roche TCRC, Inc. $5,414.40 10/15/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682550
Principal investigator 1 ABBVIE INC. $6,453.20 10/09/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202516211
Principal investigator 1 Novo Nordisk AS $286.00 09/19/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
NN6535-4725 No dispute reported 06/30/2026 1214104365
Principal investigator 1 Eisai Inc. $668.70 09/15/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244562037
Principal investigator 1 ABBVIE INC. $234.56 09/11/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202510820
Principal investigator 1 Roche TCRC, Inc. $1,892.00 09/11/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682546
Principal investigator 1 PFIZER INC. $7,754.41 08/29/2025 Non-covered Recipient Entity
Visionary Investigators Network
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228789075
Principal investigator 1 Eli Lilly and Company $3,750.00 08/28/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187893454
Principal investigator 1 ABBVIE INC. $5,793.36 08/27/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202506109
Principal investigator 1 Roche TCRC, Inc. $179.00 08/27/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682540
Principal investigator 1 Roche TCRC, Inc. $2,400.00 08/27/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682548
Principal investigator 1 PFIZER INC. $2,026.35 08/15/2025 Non-covered Recipient Entity
Visionary Investigators Network
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228766927
Principal investigator 1 Roche TCRC, Inc. $217.65 08/14/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682542
Principal investigator 1 Roche TCRC, Inc. $2,266.20 08/14/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682544
Principal investigator 1 ABBVIE INC. $3,492.56 08/13/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202504475
Principal investigator 1 Eisai Inc. $12,805.20 08/11/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244562031
Principal investigator 1 UCB SA $12,842.00 08/07/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246658760
Principal investigator 1 ABBVIE INC. $13,770.90 08/05/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202501698
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,490.83 07/28/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) No dispute reported 06/30/2026 1235991901
Principal investigator 1 ABBVIE INC. $154.69 07/22/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202499136
Recipient Amneal Pharmaceuticals LLC $84,102.30 07/22/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530903
Recipient Amneal Pharmaceuticals LLC $84,102.30 07/22/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530910
Principal investigator 1 PFIZER INC. $450.00 07/18/2025 Non-covered Recipient Entity
Visionary Investigators Network
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228764818
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $35,961.89 07/14/2025 Non-covered Recipient Entity
Visionary Investigators Network
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) No dispute reported 06/30/2026 1235991899
Principal investigator 1 Eisai Inc. $5,693.40 07/07/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244562027
Principal investigator 1 ABBVIE INC. $13,577.20 07/02/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202494643
Principal investigator 1 PFIZER INC. $15,400.00 07/02/2025 Non-covered Recipient Entity
Visionary Investigators Network
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228783942
Principal investigator 1 ABBVIE INC. $1,316.25 06/19/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202492435
Principal investigator 1 Roche TCRC, Inc. $7,006.50 06/13/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682530
Principal investigator 1 Roche TCRC, Inc. $511.00 06/05/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682534
Principal investigator 1 ABBVIE INC. $16,139.55 06/03/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202488545
Principal investigator 1 ABBVIE INC. $154.69 05/22/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202485997
Principal investigator 1 Eli Lilly and Company $7.56 05/15/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187893284
Principal investigator 1 ABBVIE INC. $83.20 05/08/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202484539
Principal investigator 1 Roche TCRC, Inc. $179.00 05/08/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682536
Principal investigator 1 Roche TCRC, Inc. $179.00 05/08/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682538
Principal investigator 1 ABBVIE INC. $8,768.50 05/06/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202481869
Principal investigator 1 ABBVIE INC. $93.75 04/24/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202479413
Principal investigator 1 Roche TCRC, Inc. $3,600.00 04/24/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682532
Principal investigator 1 ABBVIE INC. $100.00 04/23/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202478587
Principal investigator 1 ABBVIE INC. $93.75 04/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202477764
Principal investigator 1 ABBVIE INC. $81.25 04/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202477792
Principal investigator 1 ABBVIE INC. $3,507.19 04/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202477796
Principal investigator 1 ABBVIE INC. $81.25 04/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202477800
Principal investigator 1 ABBVIE INC. $2,000.00 04/04/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202474490
Principal investigator 1 ABBVIE INC. $14,353.95 04/03/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202471025
Principal investigator 1 Novo Nordisk AS $1,549.26 03/28/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
NN6535-4725 No dispute reported 06/30/2026 1214103541
Principal investigator 1 Roche TCRC, Inc. $838.00 03/27/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682522
Principal investigator 1 Roche TCRC, Inc. $550.00 03/27/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682524
Principal investigator 1 Roche TCRC, Inc. $81.00 03/27/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682528
Principal investigator 1 Eli Lilly and Company $37.50 03/25/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187892926
Principal investigator 1 Eisai Inc. $87.70 03/18/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244562025
Principal investigator 1 ABBVIE INC. $389.25 03/13/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202463809
Principal investigator 1 ABBVIE INC. $8,918.00 03/06/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202456546
Principal investigator 1 ABBVIE INC. $3,145.50 03/06/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202459019
Principal investigator 1 Novo Nordisk AS $779.76 02/21/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
NN6535-4725 No dispute reported 06/30/2026 1214102859
Principal investigator 1 Eli Lilly and Company $4,137.65 02/10/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187893682
Principal investigator 1 ABBVIE INC. $4,500.00 02/06/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202446798
Principal investigator 1 ABBVIE INC. $650.00 02/06/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202446803
Principal investigator 1 ABBVIE INC. $3,150.00 02/06/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202446811
Principal investigator 1 ABBVIE INC. $4,500.00 02/06/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202446818
Principal investigator 1 ABBVIE INC. $3,150.00 02/06/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202447249
Principal investigator 1 ABBVIE INC. $3,150.00 02/06/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202447253
Principal investigator 1 ABBVIE INC. $3,150.00 02/06/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202447257
Principal investigator 1 ABBVIE INC. $3,150.00 02/06/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202447261
Principal investigator 1 ABBVIE INC. $21,788.65 02/05/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202443964
Principal investigator 1 Eli Lilly and Company $84,003.00 02/03/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187892920
Principal investigator 1 Eli Lilly and Company $5,619.60 01/31/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187892676
Principal investigator 1 Eli Lilly and Company $4,146.87 01/27/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187892242
Principal investigator 1 Eli Lilly and Company $1,011.13 01/27/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187892740
Principal investigator 1 Eli Lilly and Company $179,168.35 01/22/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187892672
Principal investigator 1 UCB SA $21,253.00 01/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE (AD), FOLLOWED BY AN OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1246658496
Principal investigator 1 ABBVIE INC. $10,633.51 01/16/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202439763
Principal investigator 1 Roche TCRC, Inc. $7,259.40 01/16/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211682526
Principal investigator 1 Eli Lilly and Company $301.80 01/09/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187893684